Innotox, Coretox and Meditoxin: How Korean Botulinum Toxin Brands Compare

Innotox, Coretox and Meditoxin are three botulinum toxin type A products from the Korean manufacturer Medytox, and they differ chiefly in formulation, in the accessory proteins they contain, and in where they are approved for use.

If you are consulting at a clinic in Seoul and the coordinator asks which toxin you would prefer, the question is rarely about potency. All three are botulinum toxin type A, and all three relax muscle by the same mechanism. What separates them is how the product arrives at the clinic, what else is in the vial besides the toxin itself, and which regulatory authorities have reviewed them. Those differences matter more for storage, handling and cross-border comparison than for the result you see in the mirror six weeks later. This guide sets out what is actually different, what the published evidence does and does not establish, and which questions are worth asking before you agree to a particular brand.

What these three products are

Meditoxin is Medytox's original botulinum toxin type A, launched in Korea in the mid-2000s and sold in some export markets under the name Neuronox. It is supplied as a freeze-dried powder that the clinic reconstitutes with saline before injection. Innotox, introduced later, is a liquid formulation supplied ready to use, which removes the reconstitution step. Coretox is Medytox's complexing-protein-free formulation, developed to contain neither the accessory proteins found in conventional toxin preparations nor animal-derived excipients. All three are type A toxins acting at the neuromuscular junction; none is a different toxin serotype.

Formulation: why liquid versus powder matters

Conventional botulinum toxin arrives as a powder and must be reconstituted with sterile saline at the clinic. The dilution the clinician chooses affects how far the product spreads through tissue, which in turn affects how precisely a small muscle such as the depressor anguli oris can be treated. Reconstitution is routine, but it introduces a step where dilution can vary between clinics and between sessions.

Innotox arrives already in solution at a fixed concentration, so that variable is removed. In practice this means the dose you receive is more reproducible between visits, which is useful if you are treating the same areas over several years and want a consistent outcome. It also shortens preparation time. The trade-off is that liquid formulations generally have stricter cold-chain requirements, and a clinic that handles a low volume of a particular product may hold less stock. Neither format is inherently superior; they solve different practical problems.

Accessory proteins and the complexing-protein question

Botulinum toxin as produced by the bacterium is naturally bound to a complex of accessory proteins. Most commercial preparations retain some of these, and most also include human serum albumin as a stabiliser. Coretox is formulated without the complexing proteins and without animal- or human-derived components.

What the accessory proteins are thought to do

The clinical argument for removing them concerns immunogenicity. The hypothesis is that accessory proteins may contribute to the formation of neutralising antibodies, and that a patient who develops such antibodies may respond progressively less well to repeat treatment. Secondary non-response of this kind is well described in the literature, particularly in therapeutic use at high doses, such as for cervical dystonia. Whether it is a meaningful concern at the much lower doses typical of aesthetic treatment is less settled. Reported rates of clinically significant antibody-mediated non-response in cosmetic dosing are low, and direct head-to-head trials comparing complexing-protein-free products against conventional ones over many years are limited. A clinician who tells you a protein-free product will definitely prevent resistance is overstating what has been shown. A reasonable position is that the theoretical rationale is coherent, that the risk it addresses is small in aesthetic use, and that it may matter more if you expect frequent, high-dose treatment over decades.

Units, dosing and why brands are not interchangeable on paper

Botulinum toxin dosing is expressed in units, but a unit is defined by each manufacturer's own potency assay. Units are therefore not officially interchangeable between products, and regulatory labelling for every major toxin states this explicitly. In everyday Korean aesthetic practice, clinicians commonly treat Medytox units and those of the most widely known Western product as broadly comparable for facial work, and dose accordingly. That is a clinical convention supported by practitioner experience rather than a regulatory equivalence.

The practical consequence for a travelling patient is that you should record the product name and the number of units injected per area, not just the total. If you later have treatment elsewhere, that record lets the next clinician reason about your history rather than guess. Ask for it in writing before you leave.

Onset, duration and what the evidence supports

Across botulinum toxin type A products used in aesthetic doses, published trials and clinical experience generally place onset at roughly two to five days, peak effect at around two weeks, and meaningful duration in the region of three to four months for glabellar lines, with wide individual variation. Comparative studies of Korean toxins against established reference products, several indexed in PubMed, have generally reported non-inferiority for glabellar line severity at the primary endpoint.

What the evidence does not support is a claim that any one of these three lasts markedly longer than the others. Duration in an individual is influenced by dose, injection technique, muscle mass, metabolism and how expressive the treated muscles are. If a clinic promises a specific number of months, treat that as marketing rather than prognosis. Expect a range, and expect your own range to become predictable only after two or three sessions.

Regulatory status differs by country, and it changes

All three products are Korean-licensed for use in Korea, under the oversight of the Ministry of Food and Drug Safety. None of them holds the same approvals in the United States or across the European Union that the long-established Western toxins do, and some are not authorised in those markets at all.

Why this matters even if you are treated in Korea

Two reasons. First, if you develop a delayed problem after returning home, a clinician in your own country may be unfamiliar with the specific product and will want the name, lot number and dose. Second, Korean regulatory status for individual products and manufacturing lots has changed over time, and Medytox in particular has been the subject of regulatory proceedings in Korea concerning manufacturing and licensing matters. Approval status is therefore a point-in-time fact, not a permanent property. Ask the clinic to confirm that the product being used holds current Korean approval on the day of your treatment, and ask to see the vial. A clinic that treats this as an unreasonable request is telling you something useful.

How to have this conversation at the clinic

Lead with your situation rather than a brand name. Say whether you have had toxin before, whether the effect has seemed to weaken over successive sessions, how often you intend to repeat treatment, and whether you have any history of neuromuscular disease, which is a contraindication for all botulinum toxin products. Ask the injector which product they use most and why, because familiarity with a product's spread and dilution behaviour is a genuine contributor to a good result.

Reasonable questions include: which product do you propose and what is the unit dose per area; is it currently approved in Korea; how is it stored; what is your protocol if the effect is weaker than expected at the two-week review; and will the two-week review be included in the quoted price or charged separately. Avoid choosing on price per unit alone, since unit counts and dilutions differ and a low headline price can reflect a smaller dose rather than a better deal.

Frequently asked questions

Is one of these three better for a first-time patient?

No published evidence establishes a clear advantage for a first-time aesthetic patient. Injector skill, dose and placement have far more influence on your result than the choice among these three. Choose the clinic and the injector first.

Does a complexing-protein-free toxin prevent resistance to treatment?

It is designed to reduce a theoretical contributor to antibody formation, but it cannot be described as preventing resistance. Evidence in low-dose aesthetic use is limited, and secondary non-response is uncommon at these doses regardless of product.

Can I get the same product when I go home?

Often not. These products are not approved in every market, so continuity of the exact brand may not be possible. Keeping a written record of product, units and injection sites lets a clinician elsewhere translate your history into their own formulary.

Is the liquid formulation safer than the powder?

Neither format has been shown to be safer. The liquid formulation removes clinic-side reconstitution variability; the powder allows the clinician to select a dilution suited to the area being treated. Both are handled routinely in Korean practice.

How long should I stay in Korea after toxin treatment?

Botulinum toxin injection itself does not usually require an extended stay, but the effect is not assessable until roughly two weeks, which is after most visitors have left. If a two-week review matters to you, ask before booking how the clinic handles remote review and whether any touch-up would be free, discounted or chargeable.

Where to go from here

Treat the brand question as secondary. Establish first that your injector is appropriately qualified and experienced in the specific areas you want treated, that the product being used holds current Korean approval, and that you will leave with a written record of product, units and sites. If you are planning treatment as part of a trip to Korea, build in the two-week review question before you book flights, because that single scheduling detail causes more disappointment than any difference among these three products. Browse our guides on verifying a Korean clinic and on reading a Korean treatment quote to prepare the rest of your consultation.

Sources and further reading: Ministry of Food and Drug Safety (Korea) product licensing information; Korea Health Industry Development Institute materials on treatment of foreign patients; Korean Society of Plastic and Reconstructive Surgeons; comparative botulinum toxin trials indexed in PubMed. This article is general information and is not a substitute for individual medical assessment.